Right Ventricular Failure and Congenital Heart Disease

Kendsersky, Payton; Ward, Cary

doi:10.1016/j.ccl.2020.02.002

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30–32 Although surgical tricuspid valve replacement or annuloplasty, interventional tricuspid valve repair, as well as right ventricular assist devices exist as therapeutic options, they merely aim to delay global heart failure and do not represent causal therapies even as a consequence of left-sided heart failure. 33–35…”

Section: Discussionmentioning

confidence: 99%

“…[30][31][32] Although surgical tricuspid valve replacement or annuloplasty, interventional tricuspid valve repair, as well as right ventricular assist devices exist as therapeutic options, they merely aim to delay global heart failure and do not represent causal therapies even as a consequence of left-sided heart failure. [33][34][35] The evaluation of novel cardiac biomarkers to assess RVF is strongly needed. In order to avoid potential bias from left-heart pathologies, e.g.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Copeptin reliably reflects longitudinal right ventricular function

et al. 2021

View full text Add to dashboard Cite

Background: Data is limited evaluating novel biomarker and right ventricular dysfunction. Normal right ventricular function (RVF) improves the prognosis of patients suffering from heart failure. Therefore, the study investigates the association between the biomarker copeptin and right heart function compared to NT-proBNP. Methods: Patients undergoing echocardiography were enrolled prospectively. RVF was assessed by TAPSE, right ventricular and atrial parameters. Exclusion criteria were age under 18 years, LVEF < 50 % and moderate to severe valvular heart disease. Blood samples were taken for measurements within 72 hours of echocardiography. Results: 91 patients were included. Median values of copeptin increased significantly according to decreasing values of TAPSE (p = 0.001; RVF grade I: Tricuspid annular plane systolic excursion; TAPSE > 24 mm: 5.20 pmol/l; grade II: TAPSE 18 - 24 mm: 8.10 pmol/l; grade III: TAPSE < 18 mm: 26.50 pmol/l). Copeptin levels were able to discriminate patients with decreased right ventricular function defined as TAPSE < 18 mm (area under the curves (AUC): copeptin: 0.793; p = 0.001; NT-proBNP: 0.805; p = 0.0001). Within a multivariate linear regression model copeptin was still independently associated with TAPSE (copeptin: T: -4.43; p = 0.0001; NT-proBNP: T: -1.21; p = 0.23). Finally, copeptin levels were significantly associated with severely decreased RVF (TAPSE < 18 mm) within a multivariate logistic regression model (copeptin: odds ratio (OR): 0.94; 95 % confidence interval (CI): 0.911-0.975; p=0.001). Conclusions: This study demonstrates that the novel biomarker copeptin reliably reflects RVF assessed by standardized transthoracic echocardiography compared to NT-proBNP.

show abstract